secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001213900-23-018537
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics FY2022 net loss $37.7M; expands briquilimab to chronic urticaria, raises $101.4M
--------------------------------------------------------------------------------

- FY2022 net loss $37.7M vs $30.6M in 2021; R&D $34.6M, G&A $16.6M.
- Cash $38.3M at Dec 31; raised $101.4M net in Jan 2023; expects funding through 2024.
- Expanding briquilimab to chronic spontaneous urticaria; 12/12 AML engraftment, 8/12 relapse-free at 1yr.
- Appointed Vishal Kapoor to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/0001213900-23-018537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023018537/ea174835-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-018537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer